Myeloproliferative Neoplasm Diagnosis and Management

Diagnostic Approach

• The National Comprehensive Cancer Network recommends molecular testing for JAK2, CALR, and MPL mutations, and BCR-ABL testing to rule out CML, if myeloproliferative disorder is suspected, with bone marrow biopsy if indicated 1

Treatment and Management

• The National Comprehensive Cancer Network suggests considering cytoreductive therapy (e.g., hydroxyurea) if myeloproliferative disorder is confirmed, in cases of leukocytosis 1
• The National Comprehensive Cancer Network recommends maintaining adequate hydration and considering prophylaxis for tumor lysis syndrome if rapid cell turnover is suspected, as part of supportive care 1
• If diagnosis of myeloproliferative neoplasm is confirmed, the National Comprehensive Cancer Network advises following disease-specific guidelines for management 1

Thrombocytopenia Management

• Immune thrombocytopenia (ITP) is a condition characterized by low platelet count, and intervention is generally not indicated until platelet count falls below 30 × 10⁹/L in asymptomatic patients, as recommended by the American College of Cardiology 2
• Elderly patients (>60 years) have a higher risk of bleeding complications with severe thrombocytopenia, with an age-adjusted risk of fatal bleeding of 13.0% in patients >60 years of age and platelet counts <30 × 10⁹/L 2
• The risk of bleeding increases linearly when platelet counts fall below 125 × 10⁹/L, according to the American College of Cardiology 3, 4
• Thrombocytopenia is associated with significantly increased risk of thrombotic events, myocardial infarction, major bleeding, and in-hospital mortality, according to the American College of Cardiology 3, 4
• Glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide) are absolutely contraindicated in thrombocytopenia due to increased bleeding risk, as recommended by the American College of Cardiology 3, 4
• Prasugrel is contraindicated due to increased bleeding risk, as recommended by the American College of Chest Physicians 5
• Unfractionated heparin should be used with caution in thrombocytopenia as it may worsen the condition, according to the Society of Critical Care Medicine 6
• Direct thrombin inhibitors (argatroban, bivalirudin) should be considered instead of heparin when anticoagulation is necessary in thrombocytopenic patients, as recommended by the American College of Cardiology 3, 4
• Anticoagulant administration recommendations based on platelet count are as follows:

• Enoxaparin dosing should be adjusted based on platelet count:

• VKA therapy management recommendations based on platelet count are as follows:

Thrombosis and VITT Management

• A D-dimer level >4000 μg/mL is concerning for VITT, especially in patients with thrombocytopenia and thrombosis, according to the BMJ 10
• Intravenous immunoglobulin (1 g/kg) should be administered immediately in cases of VITT, as recommended by the BMJ 10
• Non-heparin based anticoagulants should be used for confirmed thrombosis, and platelet transfusions should be avoided unless severe bleeding occurs, according to the BMJ 10

Immune Thrombocytopenia (ITP) Management

• Glucocorticoid therapy (prednisone 1-2 mg/kg/day) is recommended as the initial treatment for patients with immune thrombocytopenia (ITP) with platelet counts <30,000/μL, regardless of symptoms, as recommended by the American Society of Hematology 11
• IVIg can be used if a rapid increase in platelets is needed or if corticosteroids are ineffective, as stated by Blood 12

Platelet Transfusion

• Platelet transfusions should be considered in patients with active bleeding, platelet counts <10×10⁹/L, or before invasive procedures, with specific thresholds for different procedures, as recommended by the American Association of Blood Banks and the American Society of Anesthesiologists 8, 13, 12
• The following procedure-specific platelet count thresholds are recommended:

• Active significant bleeding may be an indication for platelet transfusion despite a count of 80,000/μL 14
• Neurosurgery or ophthalmic surgery may require a higher threshold of 100,000/μL for platelet transfusion 14
• Presence of platelet dysfunction (medications, uremia) may be an indication for platelet transfusion 15

Patient Education and Lifestyle Modifications

• Patients should maintain limited alcohol intake (≤1 drink/week) and avoid binge drinking, report any new bleeding symptoms, and avoid medications that affect platelet function (aspirin, NSAIDs), as recommended by the American College of Sports Medicine 16
• Patients with platelet counts below 50 × 10⁹/L should avoid activities with high risk of trauma, as advised by the American College of Sports Medicine 11

Pregnancy and Thrombocytopenia

• Regular platelet count monitoring is recommended throughout pregnancy, according to the American College of Obstetricians and Gynecologists 2
• Mode of delivery should be based on obstetric indications rather than platelet count alone, as recommended by the American College of Obstetricians and Gynecologists 2
• For cancer patients with VTE and thrombocytopenia, therapeutic anticoagulation may be administered if platelet count can be maintained above 50 × 10⁹/L, and half-dose anticoagulation can be considered for platelet counts between 20-50 × 10⁹/L, as recommended by the American College of Cardiology 9

Heparin-Induced Thrombocytopenia (HIT) Management

• If HIT is suspected, immediately discontinue all heparin products, and initiate a non-heparin anticoagulant, such as argatroban, bivalirudin, danaparoid, fondaparinux, or DOAC, as recommended by the American College of Chest Physicians 17
• Platelet count monitoring frequency should be based on risk: